InvestorsHub Logo
Post# of 252300
Next 10
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 42379

Thursday, 02/22/2007 10:21:44 PM

Thursday, February 22, 2007 10:21:44 PM

Post# of 252300
ANDS ANA380 addendum:

On today’s CC, the rationale for the delay getting the phase-2b trial started was the difficulty of gaining approval for a multinational protocol. This, IMO, is codespeak for a clinical trial that investigators don’t strongly believe in because they don’t believe in the drug to be tested. (GENR used essentially the same language to justify the delay in starting one of the phase-3 Evizon trials until they finally admitted that the situation was hopeless.)

As support for my contention, I offer this:

1. Almost a year has elapsed since the end of phase-2a (#msg-11806828).

2. NVS passed on exercising an exclusive option to license ANA380 (#msg-12538617). Note that this decision occurred before Tyzeka was approved in any jurisdiction of consequence.

3. ANDS and partner LG of Korea are not even talking about running a trial that compares ANA380 to Baraclude or Tyzeka; rather they are talking about comparing ANA380 to Hepsera, which is at best second-rate in efficacy (#msg-16969129).

--
I am hereby proclaiming ANA380 a non-factor in the HBV arena. If I’m wrong, I’ll be the first to admit it.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.